1239311-43-3

Basic information

• Product Name: methyl cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylate
• Synonyms: methyl cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylate
• CAS NO: 1239311-43-3
• Molecular Weight: 487.527
• Mol File: 1239311-43-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylate(1239311-43-3)
• EPA Substance Registry System: methyl cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylate(1239311-43-3)

Safety Data

• Hazardous Substances Data: 1239311-43-3(Hazardous Substances Data)

Upstream product

• 3685-26-5 cis-4-hydroxycyclohexanecarboxylic acid 
• 3618-03-9 methyl cis-4-hydroxycyclohexanecarboxylate 
• 25804-49-3 tert-butyl 4-hydroxybenzoate 
• 105184-38-1 3,5-difluorophenyl acetic acid 
• 1239311-41-1 2-[(3,5-difluorophenyl)acetyl]hydrazinecarbothioamide 
• 1239311-42-2 5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-amine 
• 1237148-17-2 trans-4-(4-methoxycarbonylcyclohexyloxy)benzoic acid 
• 1237148-09-2 tert-butyl trans-4-(4-methoxycarbonylcyclohexyloxy)benzoate 
• 1239310-91-8 cis-4-(4-methoxycarbonylcyclohexyloxy)benzoic acid 
• 1239311-09-1 methyl cis-4-(4-chlorocarbonylphenoxy)cyclohexanecarboxylate 

Downstream Products

• 1239311-40-0 cis-4-{4-[5-(3,5-difluorobenzyl)[1.3.4]thiadiazol-2-ylcarbamoyl]-phenoxy}cyclohexanecarboxylic acid 

Relevant articles and documents

Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitors

Chemical modulation of a formerly disclosed DGAT-1 inhibitor resulted in the identification of a compound with a suitable profile for preclinical development. Optimisation of solubility is discussed and a PK/PD study is presented.